Highlights of 2018 - a look back by Sameer Kothari, Zilico CEO
Thursday 20th December 2018
It's been another great year. At the close of 2017, Zilico were named in the Global Digital Health 100, one of the HealthTech industry's foremost technology award programmes, and we've continued this success throughout 2018 as we continue to grow and be recognised for our achievements.
This year Zilico's flagship product, ZedScan™, saw futher adoption across the UK and Europe with Aberdeen Royal Infirmary, Birmingham Women's Hospital and Helsinki University Central Hospital, Finland now all routinely using ZedScan in their clinics. In addition, we have 6 service evaluations underway with 3 converting to routine adoption in early 2019.
As we move into primary HPV screening in 2019, we are confident that more clinicians, patients and Trusts will benefit from ZedScan as it continues to evidence increased detection of disease in the HPV positive/cytology negative cohort.
Zilico's supply to the NHS was celebrated in October when we were awarded the NHS in the North Excellence in Supply, Clinical Innovation Award 2018.
Strategic Investments and Growth
Early 2018 saw Zilico secure $19 million from New Investments, with a $7million investment from Deepbridge Capital (UK) and a strategic deal with Maxhealth Medicine Group (China). The deal will see Zilico receive minimum royalties of $12million and will support our global ambitions to bring ZedScan to China and move towards FDA approval for the worlds largest medical device market.
In November, this deal was recognised at the 2018 Bionow Awards, winning Investment Deal of the Year, where we were also shortlisted for the Company of the Year Award.
Our distribution network also grew as partnerships with Hospital Services Limited (HSL), Ireland, Mobile SCANMED Systems, Poland, Maz Medical, Greece, Kebomed, Finland, GAP in Mexico and Vedera in Australia were agreed. These distributors will ensure that ZedScan users across Europe have local support and will drive further geographical expansion.
While ZedScan adoption continues to spread, so does Zilico's reputation. In August, Pathfinders Consultants LLP were awarded a Medical Technology / Devices Healthcare Excellence Award by the Federation of Indian Chambers of Commerce and Industry for their work with ZedScan in India.
In September, I was invited by Matt Hancock, UK Secretary of State for Health and Social Care, and Andy Burnham, Mayor of Greater Manchester, to attend the Word Economic Forum in China.
I was also invited onto the GIANT Health Innovators Live Show, to speak about the challenges of technology adoption in the NHS and how our EIS technology is being developed to determine tissue margins in surgery.
Zilico's journey to success and growth was supported by the Enterprise Investment Scheme and recognised in the 100 Stories of Growth.
Our Team keeps growing
This year we were joined by Darren Kell, Head of Research; Pippa Johnson-Tait, Clinical Specialist and Kirsty Cook, Head of QA/RA
Dr Warner Huh, Associate Professor of Gynecologic Oncology, University of Alabama, Birmingham and President of ASCCP (US) joins our Medical Advisory Board.
Zilico continue to support Jo's Cervical Cancer Trust, fundraising through our consumable sales and driving screening awareness. We also continue our sponsorship of the Sheffield Medics Women's Football Club and Gynae Allsorts: ladies netball team at Jessops Wing.
Looking Forward to 2019
Our passionate Zilico team are not only focussed on driving the continued success of the business, but are committed to improving clinical pathways for clinicians and patients. As we look forward to 2019, we do so with our ambition for ZedScan as the 4th screening tool and for Zilico to be a part of the legacy of global eradication of cervical cancer. I would like to thank all of our supporters and look forward to what we know will be another outstanding year.